Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary
cancer treatment modality, offering long-lasting responses and survival benefits for a …

Currently, immunotherapy targeting programmed cell death 1 (PD-1) or programmed death
ligand 1 (PD-L1) has revolutionized the treatment strategy of human cancer patients …

Obesity is a major driving factor in the incidence, progression, and poor treatment response
in gastrointestinal cancers. Herein, we conducted a comprehensive analysis of the impact of …

Abstract The phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free
survival (PFS) in patients (N= 886) with advanced renal cell carcinoma treated with first-line …

Plasmacytoid dendritic cells (pDCs) are a pioneer cell type that produces type I interferon
(IFN-I) and promotes antiviral immune responses. However, they are tolerogenic and, when …

Oral leukoplakia is the most frequent and potentially malignant lesion of the oral cavity.
Although dysplasia grading remains the main factor for risk assessment, challenges persist …

Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular
carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro …

Simple Summary The United States is suffering from an epidemic associated with infections
with the Human Papilloma Virus (HPV) that are responsible for the development of head and …

Simple Summary This retrospective study explores how tumor cells impact the surrounding
tissue, creating what is known as the tumor microenvironment. This environment, consisting …

The tumor microenvironment (TME), composed of and influenced by a heterogeneous set of
cancer cells and an extracellular matrix, plays a crucial role in cancer progression. The …